The advance in synthetic biology: towards a microbe-derived paclitaxel intermediates.
- Author:
Wei WANG
1
;
Yan YANG
;
Xiao-Dong ZHENG
;
Shu-Qiong HUANG
;
Lei GUO
;
Jian-Qiang KONG
;
Ke-Di CHENG
Author Information
1. State Key Laboratory of Bioactive Substances and Functions of Natural Medicines & Key Laboratory of Biosynthesis of Natural Products, Ministry of Health of PRC, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. wwang@imm.ac.cn
- Publication Type:Journal Article
- MeSH:
Alkenes;
chemistry;
metabolism;
Antineoplastic Agents, Phytogenic;
biosynthesis;
chemistry;
metabolism;
Biosynthetic Pathways;
Diterpenes;
chemistry;
metabolism;
Escherichia coli;
metabolism;
Fermentation;
Metabolic Engineering;
Paclitaxel;
biosynthesis;
chemistry;
metabolism;
Prodrugs;
Saccharomyces cerevisiae;
metabolism;
Synthetic Biology
- From:
Acta Pharmaceutica Sinica
2013;48(2):187-192
- CountryChina
- Language:Chinese
-
Abstract:
The synthetic biology matures to promote the heterologous biosynthesis of the well-known drug paclitaxel that is one of the most important and active chemotherapeutic agents for the first-line clinical treatment of cancer. This review focuses on the construction and regulation of the biosynthetic pathway of paclitaxel intermediates in both Escherichia coli and Saccharomyces cerevisiae. In particular, the review also features the early efforts to design and overproduce taxadiene and the bottleneck of scale fermentation for producing the intermediates.
